Moneycontrol Be a Pro
Get App
you are here: HomeNewsBusiness
Last Updated : Jul 30, 2018 02:22 PM IST | Source: PTI

Nod for Aurobindo Pharma to make, market Bivalirudin injection

In a press release here, Aurobindo Pharma Ltd said the drug was a generic equivalent to the Angiomax injection.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Aurobindo Pharma Limited today said it got the approval of the US Food and Drug Administration (USFDA) to manufacture and market Bivalirudin injection of 250 mg/vial.

In a press release here, Aurobindo Pharma Ltd said the drug was a generic equivalent to the Angiomax injection.

The Bivalirudin injection was being used as an anti-coagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty among others, the release said.

Close
The drug was intended for use with aspirin, it said. Citing market reports, the release said the estimated market size of the Bivalirudin injection was USD 101 million for the year ending May 2018. The product would be launched in September 2018, the release said.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Jul 30, 2018 02:17 pm
Loading...
Sections
Follow us on
Available On